GRI Bio's GRI-0621 Shows Repair Phenotype in IPF Phase 2a Trial…

Event summary

GRI Bio presented Phase 2a data at ERS 2026 showing GRI-0621's mechanism of action in IPF across nine mechanistic pillars.
Whole blood RNA sequencing and other modalities confirmed immune re-balancing, myofibroblast inhibition, and basement membrane repair.
GRI-0621-treated patients showed a 2x–2.5x higher FVC increase compared to placebo, with a placebo-adjusted change of +99 mL overall.
The study was well-tolerated with no serious adverse events reported in the GRI-0621 arm.

The big picture

GRI Bio's Phase 2a data for GRI-0621 in IPF suggests a unique repair phenotype, distinguishing it from current antifibrotics that only slow lung function decline. The findings position GRI-0621 as a potential novel therapy in a market with significant unmet needs. The next steps will be critical in determining whether the observed benefits translate into long-term clinical and commercial success.

What we're watching

Clinical Efficacy: Whether GRI-0621's observed repair phenotype and FVC improvements can be sustained in longer-duration studies.
Regulatory Pathway: The pace at which GRI Bio advances GRI-0621 into a 52-week study and potential regulatory approval.
Market Differentiation: How GRI Bio positions GRI-0621 against existing IPF treatments like nintedanib and pirfenidone.